

- b) contacting the fixed monoclonal antibody JAQ1 with a sample of the blood together with labelled antibody JAQ1,
- c) washing the solid carrier, and
- d) measuring a signal of the labelled antibody JAQ1.

**IN THE ABSTRACT OF THE DISCLOSURE**

Please delete the Abstract of the Disclosure and add the Abstract of the Disclosure on the attached sheet of paper.

**REMARKS**

**STATUS OF THE CLAIMS**

Claims 1-16 are pending. Claims 1-8 and 10-13 have been amended and new claims 14-16 have been added. The claims have been amended to recite proper antecedent basis and conform to U.S. patent practice. No new matter has been added. Prompt and favorable examination on the merits is respectfully requested.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: January 22, 2002

By: Carol L. Cole  
Carol L. Cole  
Reg. No. 43,555

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

**APPENDIX TO THE PRELIMINARY AMENDMENT FILED JANUARY 22, 2002**

**IN THE CLAIMS:**

Please substitute pending claims 1-8 and 10-13 with amended claims 1-8 and 10-13 as follows:

1. (Amended) A [Medicament] medicament for [the] protection against thrombotic diseases, **[characterized in that it comprises an]** comprising at least one active principle that induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes.

2. (Amended) The [Medicament] medicament as claimed in claim 1, **[characterized in that]** wherein the at least one active principle is an antibody [induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes].

3. (Amended) The [Medicament] medicament as claimed in claim 1, **[characterized in that it comprises**

the] wherein the at least one active principle is monoclonal antibody JAQ1.

4. (Amended) The [Medicament] medicament as claimed in [claims] claim 1 [and 2], **[characterized in that it contains an antibody against the thrombocyte collagen receptor]** wherein the collagen receptor on thrombocytes is GPVI.

5. (Amended) The [Medicament] medicament as claimed in [claims] claim 1 [to 3], **[characterized in that it contains the]** wherein the at least one active principle is humanised monoclonal antibody JAQ1.

6. (Amended) A diagnostic agent for the determination of the expression rate of [the] a collagen receptor GPVI, **[characterized in that it contains a]** comprising

FINNEGAN  
ENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

at least one labelled antibody chosen from a monoclonal antibody and a [or] polyclonal antibody, wherein the at least one labelled antibody is directed against [the] a GPVI epitope[, preferably as defined by JAQ1].

7. (Amended) A method for the determination of the expression rate of [the] a collagen receptor GPVI in blood [characterized in that] of a patient comprising:

a) incubating a sample of the blood [of the patient is incubated] with a solid carrier on which [the] antibody JAQ1 is fixed,

b) washing the solid carrier,

c) incubating [it] the washed solid carrier with a second labelled antibody JAQ1,

d) washing the carrier again, and

e) measuring [the] a signal of the second labelled antibody[; or

b) a sample of the blood of the patient is fixed on a solid carrier and thereafter treated with the labelled antibody JAQ1 alone or in mixture with the unlabelled antibody JAQ1 and subsequently the labelled antibody is detected; or

c) the monoclonal antibody JAQ1 is fixed on a solid carrier and is thereafter contacted with the blood sample, which is to be tested, together with the labelled antibody JAQ1, washing the carrier and measuring the signal of the labelled antibody].

8. (Amended) [A] The method [is] as claimed in claim [6] 7, [**characterized in that** it is performed] wherein the signal is measured in a flow-cytometer using a [fluorescence-labelled] fluorescence-labelled monoclonal JAQ1 antibody [in a flow-cytometer].

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

10. (Amended) Monoclonal antibody[, characterized in] that [it] binds to the same or a similar [epitop] epitope of [the] a collagen receptor for thrombocytes as [the] monoclonal antibody JAQ1.

11. (Amended) A method [Use of the active principle that induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes] for [the preparation of] producing a medicament against thrombotic diseases comprising providing at least one active principle that induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes.

12. (Amended) [Use] The method as claimed in claim 11, wherein the at least one active principle is a monoclonal antibody.

13. (Amended) [Use] The method as claimed in [claims] claim 11 [and 12], wherein the at least one active principle is [the] a monoclonal antibody JAQ1.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com